Moneycontrol
HomeNewsBusinessEarningsGodrej Agrovet: Q2 margin remain compressed; buy for the long term
Trending Topics

Godrej Agrovet: Q2 margin remain compressed; buy for the long term

Although some hurdles in the operating environment have curbed growth at present, we expect these to stabilise and overall earnings to improve in FY19

November 13, 2018 / 13:40 IST
Story continues below Advertisement

Ruchi Agrawal Moneycontrol Research

Godrej Agrovet (GAVL) reported a subdued Q2 FY19 earnings, with mixed performance across segments. Revenue saw a healthy 7 percent year-on-year (YoY) uptick on the back of a healthy volume growth. However, earnings before interest, tax, depreciation and amortisation (EBITDA) margin saw a sharp 160 basis points (100 bps = 1 percentage point) contraction due to impact on aqua feed, palm oil and dairy segment margins. Uptick in the other income includes proceeds from the sale of land, which led to an uptick in net profit, excluding which overall profitability remained compressed.

Story continues below Advertisement

Animal feed The 16 percent volume growth was driven by layer and broiler feed business, which led to a healthy 16.3 percent sales growth for the segment. High input cost and low pricing power in the shrimp feed segment impacted profitability of the aqua feed business.

Low milk prices continued to impact pricing in the cattle feed business, where margin remained subdued. GAVL is strategically focussing on gaining volumes going forward, which, as per the management, might impact margin in the short term. However, the company would stand to benefit in the longer run as better plant utilisation levels leads to lower cost of production.

Sale of products below the minimum support price (MSP) in the current kharif season augurs well to lower procurement cost for raw materials in the animal feed segment.

Crop protection The crop protection segment posted a 25.2 percent growth in revenue and a 15.4 percent growth in profit. Strong performance was a result of strong traction from new products launched in the past quarters. Astec Lifesciences posted a 17.4 percent revenue growth and a 430 bps EBITDA margin expansion.